Nimesulide Ratiopharm and Flexiban
PreclinicalSmall molecule
Nimesulide Ratiopharm and Flexiban is one of 11 small molecule programs targeting Temporomandibular Joint Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Temporomandibular Joint Disorder
#DrugCompanyPhaseTrials
1Nurtec
PfizerApproved
Aleve
Jazz PharmaceuticalsApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Ketalar
AAultman Health Foundation
Approved
Cymbalta
Jazz PharmaceuticalsPreclinical
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Preclinical
Alcohol
AstellasPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Roma La Sapienza